Share: Facebook Twitter LinkedIn
Activity Provided By:

i3 Health

Novel Breast Cancer Therapies: PARP Inhibitors

Access Activity

Overview / Abstract:

STATEMENT OF NEED

Breast cancer is the most commonly diagnosed cancer in women. A BRCA1 or BRCA2 mutation is found in approximately 5% of patients with breast cancer and is detected in 30% of patients who have a family history of breast or ovarian cancer (ACS, 2019). In patients with human epidermal growth factor receptor 2 (HER2)"negative breast cancer with deleterious or suspected deleterious germline BRCA mutations, inhibition of poly"(ADP-ribose) polymerase (PARP) is highly efficacious, even in early breast cancer. PARP inhibitors block pathways involved in DNA single-stranded break repair. In combination with a germline or somatic mutation impacting the homologous recombination DNA repair genes BRCA1 or BRCA2, PARP inhibition leads to stalled replication, DNA damage, and cancer cell death (Cortesi et al, 2021). In this session, Janie Metsker, RN, BSN, CN-BN, will explain the benefit of PARP inhibitors for breast cancer in patients with germline BRCA mutations and will present the latest data justifying the recent approval of olaparib for adjuvant therapy in high-risk early breast cancer (Tutt et al, 2021). She will also highlight the side effect profiles of PARP inhibitors and the importance of counseling patients about the side effects they may experience.

TARGET AUDIENCE

Oncology nurses, nurse practitioners, physician assistants, pharmacists, oncologists, and other health care professionals involved in the treatment of patients with breast cancer.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to
Assess the indications and safety and efficacy profiles of novel PARP inhibitors for breast cancer
Evaluate clinical tools for assessing and grading adverse events associated with novel PARP inhibitors
Apply strategies to optimize the safety and tolerability of novel PARP inhibitors
Develop educational strategies to help patients understand the benefits and risks of their breast cancer treatment plan

Expiration

Dec 06, 2023

Discipline(s)

Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME

Format

Online

Credits / Hours

1.0 CME | 1.0 NCPD | CPE | MOC | ILNA

Accreditation

ACCME, ANCC

Presenters / Authors / Faculty

Janie Metsker, RN, BSN, CN-BN
Clinical Coordinator
Saint Luke's Hospital
Koontz Center for Advanced Breast Cancer

Sponsors / Supporters / Grant Providers

This activity is supported by independent educational grants from Gilead Sciences, Inc. and Puma Biotechnology.

Keywords / Search Terms

Oncology, i3 Health, CME, NCPD, free CNE, free NCPD, Free CE, Free CME, Nursing, Oncology Nursing, Breast Cancer, Breast Cancer Therapies, Physician, Oncology Physician, PARP Inhibitors

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map